Thermo Fisher Scientific (TMO) recently unveiled the PlasmidPro Maxi Processor (PlasmidPro), its latest addition to the Thermo Scientific KingFisher instrument portfolio. The solution has a comprehensive range of key features that sets it apart as the only fully automated maxi-scale plasmid DNA (pDNA) purification system. The company's newest development is expected to significantly enhance the Biosciences business under the Life Sciences Solutions segment. More on the PlasmidPro System The PlasmidPro purif ...

Thermo Fisher Scientific Inc. (TMO) has announced a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, WI, under its PPD clinical research business. The addition of a 72,500-square-foot building is likely to improve the company's clinical development and laboratory services by expanding the site's chemistry, manufacturing and control (CMC) analytical capabilities. This, in turn, should help its customers provide high quality and safety standards for patient ...

Thermo Fisher (TMO) gains from strong end-market performances. International issues continue to hamper overall growth. The stock carries a Zacks Rank #3 (Hold) currently. Within the pharma and biotech end market, of late, Thermo Fisher's biosciences and bioproduction businesses have significantly expanded their capacity to meet global vaccine manufacturing requirements. Additionally, the pharma services business has been providing pharma and biotech customers with the services they need to develop and produ ...

Thermo Fisher Scientific (TMO) recently introduced the Thermo Scientific Heracell VIOS 250i AxD CO Incubators to support the future implementation of workflow automation in cell therapy production. These 2 first-of-their-kind CO incubators are designed for integration into automated and modular laboratories. 2 The latest development from Thermo Fisher represents the most advanced incubators in the VIOS portfolio. The company’s VIOS family of incubators is known for optimal cell growth conditions and minimal ...

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Thermo Fisher Scientific Inc (TMO) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competi ...

Thermo Fisher Scientific Inc. (TMO) is gaining investors’ confidence due to its impressive partnerships. Of late, the company has launched a slew of products to enhance its portfolio. Strong, stable solvency also buoys optimism. However, declining COVID-19 sales, as well as adverse macroeconomic impacts, might deter Thermo Fisher’s growth. In the past year, this Zacks Rank #3 (Hold) stock has rallied 11.3% compared with the 8.4% rise of the industry and 25.5% growth of the S&P 500 composite. The renowned me ...

文章核心观点 - 公司是一家专注于为医疗和生物技术行业提供创新产品和服务的供应商 [8][9][10] - 公司通过战略性并购如PPD和Patheon,不断拓展服务能力,成为制药公司的可靠合作伙伴 [13][14] - 公司在中国市场的业务表现良好,预计未来几年将从中国政府的财政刺激计划中获益 [15][16][17] - 公司专注于高端研究和前沿技术,如Orbitrap Astral质谱仪,有助于捕捉生命科学行业的快速发展 [18] 公司表现和前景 - 公司在第一季度提高了全年收入和利润指引 [18] - 公司与拜尔等大型医疗公司建立了战略合作关系,有利于未来发展 [19] - 公司股票回购和增加股息,体现了对未来发展的信心 [19] - 分析师预计公司未来2-3年的每股收益增长将达到11%-12% [21][22] - 公司当前估值略高于历史平均水平,但考虑到良好的增长前景,投资者仍看好公司 [23][24][25] - 公司长期来看有望实现高于大盘的总回报 [26] 投资评论 - 公司作为医疗和生物技术行业的关键供应商,有望持续受益于行业创新需求 [27][28] - 尽管短期内面临一些挑战,但公司的战略定位和合作关系为其未来发展奠定了良好基础 [28] - 对于追求长期增长的投资者而言,公司仍是一个有吸引力的投资标的 [27]

VANCOUVER, BC, May 23, 2024 /PRNewswire/ - Trilogy Metals Inc. (TSX: TMO) (NYSE American: TMQ) ("Trilogy Metals" or the "Company") is pleased to announce the detailed voting results on the items of business considered at its Annual Meeting of Shareholders ("Meeting") held in Vancouver on Wednesday, May 22, 2024. All proposals were approved and the nominees listed in the management proxy circular for the meeting were all elected as directors. A total of 98,964,326 or 61.79% of the Company's issued and outsta ...

Thermo Fisher Scientific Inc. (NYSE:TMO) Bank of America Securities 2024 Health Care Conference Call May 14, 2024 11:00 AM ET Company Participants Marc Casper - Chairman, President & Chief Executive Officer Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin Thanks everyone for joining us. For those of you who don't know me, my name is Mike Ryskin on BofA life science tools and diagnostics team. And I'm thrilled to kick off the Bank of America Las Vegas Healthcare Conference. Joining us f ...

Have you evaluated the performance of Thermo Fisher Scientific's (TMO) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this maker of scientific instrument and laboratory supplies, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets i ...